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Abstract
Background/Aims: Fabry disease (FD) is a rare inherited lysosomal storage disease with 
common and serious kidney complications. Enzyme replacement therapies (ERT) with 
agalsidase-α and -β were investigated to characterize their therapeutic effect on kidney 
function in FD patients with Classic phenotype. Methods: The prospective FD cohort consisted 
of 98 genetically confirmed patients (females, n = 61, males, n = 37). The median [interquartile 
range] follow-up time (time difference from first to last visit) was 9 [6, 12] years. The median 
age of ERT start was 36 [21 – 54] years for females and 39 [28 – 49] years for males. Results: 
A disease progression model was developed to (i) characterize the time course of estimated 
glomerular filtration rate (eGFR) and (ii) evaluate therapeutic effects of ERT on kidney function. 
Change in eGFR over time was best described by the linear model. Females had stable kidney 
function with and without ERT (eGFR slopes of -0.07 ml/min/1.73m^2 per year and 0.52 ml/
min/1.73m^2 per year, respectively). Males with ERT showed an eGFR decrease of -3.07 ml/
min/1.73m^2 per year. Conclusion: Mathematical disease progression modeling indicates 
that there is no clear therapeutic effect of ERT on kidney function in adult patients with Classic 
Albina Nowak, MD Department of Internal Medicine, University Hospital Zürich, Rämistrasse 100, 
8091 Zürich (Switzerland), Tel. 0041 44 255 10 54, Fax 0041 44 255 45 67
E-Mail albina.nowak@usz.ch
Erratum
June 15, 2017. DOI: 10.1159/000478062
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
17
60
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
 Kidney Blood Press Res 2017;42:1-15
DOI: 10.1159/000464312
Published online: February 28, 2017
© 2017 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 2
Nowak et al.: ERT and Kidney Function in Classic FD Phenotype
Introduction
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by a deficiency 
of the enzyme α-galactosidase A (α-Gal A) resulting in a progressive intralysosomal 
accumulation of glycosphingolids in different cell types, plasma and urine [1, 2]. In a 
majority of patients, initial signs and symptoms related to FD appear in childhood and 
include acroparaesthesia, angiokeratoma, abdominal pain, hypohidrosis and corneal 
dystrophy. Inflammation and fibrosis associated with disease progression leads to kidney 
and heart failure, cerebrovascular disease and early mortality [1]. Deposition of undergraded 
glycosphingolipid substrate occur in all kidney cells and structures including podocytes, 
mesangial, tubular, interstitial and vascular endothelial cells [3]. Fabry nephropathy is linked 
to cardiovascular morbidity and mortality in FD patients [4]. Although males have more 
severe Fabry disease than females, heterozygous females with X-chromosomal inactivation 
can also be severely affected depending on random X-chromosomal inactivation [5]. 
“Classic” and “Later-Onset” phenotypes are the two major FD subtypes. Affected males with 
the Later-Onset phenotype have residual α-Gal A activity, later-onset cardiac and/or renal 
disease, and lack the major early-onset classical manifestations, including angiokeratoma, 
acroparesthesias, hypohidrosis, and the ocular abnormalities [6-9].
Enzyme replacement therapy (ERT) with recombinant α-Gal A was approved in Europe 
in 2001. There are two preparations available on the market: agalsidase-α with the licensed 
dose of 0.2 mg/kg or agasidase-β dosed at 1 mg/kg body weight, each administered every 
2 weeks intravenously. ERT initiation is recommended in classically affected males and 
females as soon as early clinical signs of FD occur [10]. Studies have shown a kidney tissue 
clearance of glycosphingolipid accumulation as a result of ERT [11], long-term ERT stabilized 
and preserved kidney function in some FD patients [12-14]. Recent studies suggest that FD 
patients with chronic kidney disease (CKD) stage 3 or 4 may not benefit from ERT as clinically 
meaningful events continue to occur in these patients despite treatment [15]. Proteinuria 
seems to be associated with decreased effectiveness of ERT [16, 17]. 
To further enhance treatment strategies for FD patients, key determinants of variability 
in kidney disease progression in FD patients with and without ERT need to be identified and 
characterized. For this reason a longitudinal, mathematical model was developed [18] to (i) 
account for individual behavior of female and male FD patients, (ii) characterize individual 
model parameters and the inter-individual variability, (iii) identify and quantify effects of 
covariates on kidney disease progression, measured as change in kidney function (eGFR) 
over time. In order to analyze a homogeneous group, the performed disease progression 
analysis focused on patients with the Classic phenotype of FD.
Subjects and Methods 
This is a retrospective analysis of a prospective, multi-center cohort in Switzerland. The study was 
conducted in accordance with the principles of Helsinki Declaration. Patients who were alive were contacted, 
and signed a written informed consent.
© 2017 The Author(s)
Published by S. Karger AG, Basel
Phenotype of FD. Interpretation of these findings should take into account that the study is 
not randomized and lacks a placebo controlled group. Further investigations are warranted to 
clarify whether earlier ERT initiation before 18 years of age, higher ERT dose or more intensive 
therapies can preserve kidney function.
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Study population and clinical data
The prospective FD cohort consisted of 98 genetically confirmed patients (females, n = 61, males, n = 
37). The cohort was established in 2001 when ERT was approved and offered to FD patients. Consecutive 
FD patients were registered and monitored at two tertiary care hospitals – University Hospitals Zürich 
(90 patients) and Bern (8 patients) Switzerland. Patients on renal replacement therapy (RRT) - kidney 
transplantation or dialysis (n = 5 all male) - at baseline and patients with the Later-Onset phenotype (n=9) 
were excluded from the analysis. 
The analysis included all available renal data extracted from the FD patients` medical records until 
kidney transplantation (n = 5), death (n=10) or March 2015. Kidney function, expressed as eGFR according 
to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [19],  and proteinuria, expressed 
as protein/creatinine or albumin/creatinine ratio, were analyzed. Information on concomitant angiotensin-
converting enzyme (ACE)-inhibitors and angiotensin-receptor blockers (ARB) therapy was also recorded 
and analyzed as covariates. Kidney biopsies were performed in 11 patients, 6 males and 5 females, all the 
biopsies confirmed the Fabry nephropathy.   
Treatment 
ERT was initiated according to the written local guidelines. Accordingly, ERT was indicated in all males, 
independent from age, phenotype and symptoms. In females, ERT was indicated if they had proteinuria of 
more than 300 mg per day, Fabry-typical kidney biopsy findings, signs of Fabry cardiopathy such as left 
ventricular hypertrophy or arrhythmia, stroke or transient ischemic attack (TIA), persistent FD-related 
neuropathic pains despite conventional analgetic therapy, and or gastrointestinal symptoms. 
In all patients, ERT was prescribed at the licensed dose of either 0.2 mg/kg body weight of recombinant agalsidase-a (Replagal) or 1 mg/kg body weight agalsidase-b (Fabrazyme) and given intravenously every 
14 days. We retrospectively calculated the actual, administered ERT amount per kg by multiplying the dose 
contained in a vial by the number of vials and divided this amount by the current body weight documented 
in the medical records at each visit. We separately computed cumulative doses for Replagal and Fabrazyme 
in patients who switched ERT. Cumulative doses were calculated according to the respective preparation of 
Replagal and Fabrazyme.
Phenotyping
Phenotyping was based on GLA mutation type:  frame-shift, nonsense, consensus splice-site mutations, 
large insertions and deletions, and some missense mutations, which result in no or <2% of mean normal 
enzymatic activity were classified as having the Classic phenotype. In contrast, some missense and some 
alternative splicing mutations result in enzymes with residual enzymatic activity and the Later-Onset 
phenotype.  To determine, if the missense mutations caused the Classic or Later-Onset phenotype, clinical 
data, substrate levels, and in vitro expression assays were evaluated to determine the mutation’s phenotype 
[6, 20, 21].  
Assessment of kidney function
As measure of kidney function, the eGFR was derived from serum creatinine scr (mg/dL) and age 
(years) by the Chronic Kidney Disease Epidemiology Collaboration [19].
Characterizing relationship between age and kidney function at baseline
In a first step, the relation between age at baseline (AgeBase) and eGFR at baseline (eGFRBase) was 
investigated by linear regression 
(1)
where a is the intercept and m the slope. Female (54 subjects) and male (25 subjects) were separately 
investigated. 
Developing disease progression model to describe change in kidney function over time 
In the second step, a disease progression model [22, 23] to describe eGFR change over time was 
developed. Data of every individual was shifted to the starting time point t=0. 
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To describe eGFR change eGFR(t) over time t (months), the linear model
(2)
where eGFRBase is the initial intercept at  t=0 and eGFRSlope the slope, was most appropriate to describe 
available data. Also other disease progression models such as exponential decay or oscillating approaches 
were tested. However, estimated parameters for these models always produced a linear prediction, 
confirming our chosen linear model Eq. (2). 
Incorporating of patient characteristics and covariate effects on kidney function in model 
FD patients with more than one creatinine measurement were included into the dynamical analysis 
(n = 67). Non-linear mixed effect modeling [18, 24] was applied to estimate the typical (also called mean 
or population) parameters and individual parameters. A normal distribution for the individual eGFR slopes 
eGFRSlope,i was assumed to allow negative values for 1 < i < n where n is the number of individuals. Individual 
eGFR baselines eGFRBase,i were described best by a log-normal distribution. The variance of these parameter distributions is denoted by wƟk with 1 < k < nparm, where nparm= 2 is the number of model parameters. 
Categorical covariates CovCat, such as gender, were implemented at the individual model parameters Ɵi,k 
with
(3)
In Eq. (3), the effect of the individual covariate on the population parameter Ɵpop,k is described by 
bcovcat,k. Continuous covariates, such as age baseline, and time-varying covariates, such as age change over 
time, were implemented with the power model 
where CovCon is a covariate, Covref  a reference value of a given covariate and bcovcon,k  the coefficient 
describing the effect of the covariate. In our analysis, Covref was defined as the mean and estimated from 
data. Time-varying covariates were implemented as additional regression variables in the model. 
Kindey disease progression model according to baseline albuminuria
Patients were categorized into three groups of albuminuria according to the recent KDIGO definitions 
[25]: A1 with albuminuria < 3 mg/mmol, A2 3-30 mg/mmol, A3 > 30 mg/mmol. Computed individual 
slopes from the longitudinal analysis of treated FD patients were grouped into these three albuminuria 
categories. Albuminuria at baseline was defined as the first available measurement in each study patient.
Analysis of serum-mediated ERT inhibition
Between January 2014 and December 2016, blood for biobanking was drawn, blood samples were 
centrifuged and serum was immediately frozen at −80°C.  ERT inhibition assays were performed as 
reported elsewhere [26-28] in 15 males and 20 females who were included into the dynamical analysis. 
The measurements have been performed as triplicates. Since ERT-inhibition develops within the first weeks 
after ERT treatment [26] and seems to be irreversible, serum samples from recent visits are most likely 
useful to reflect the inhibition status over the treatment period. Patients with a mean ERT inhibition >50% 
were designated as ERT inhibition positive according to recent literature [27]. 
Statistical-mathematical analyses
Categorical variables were expressed as proportions, continuous variables as medians with interquartile 
ranges [IQR]. All statistical tests were two-sided, and p values <0.05 were considered significant.
The dynamical analysis was performed with the non-linear mixed effect software package Monolix 4.3 
[29]. The other analyses were performed using statistical software package R [30].
Results
Follow-up and treatment
The average number of visits was 5 per patient and the overall number of visits was 
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to agalsidase-a (due to shortage of agalsidase-b), two patients from agalsidase-a to agalsidase-b (due to patient`s priority) and two from agalsidase-a to agalsidase-b and back to agalsidase-a (due to logistic reasons). 
This FD cohort was analyzed to characterize the effects of ERT on the renal disease 
and progress following ERT. First, the relationship of age and eGFR calculated according to 
Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) [19] at initiation of 
ERT was investigated in Classical patients not on RRT. Second, a longitudinal analysis with a 
disease progression model was performed in patients with two or more visits. Only one male 
was untreated and therefore excluded from the analysis. Baseline characteristics of included 
patients (n =67) are summarized in Table 1. The Flow-chart is shown as Figure 1. 
Table 1. Parameter estimates of linear 
regression Eq. (1) for the age at base-
line and eGFR at baseline relationship
437. The median follow-up time of all included patients 
(time difference from first to last visit) was 9 [6 – 12] 
years. A total of 53 FD patients were on ERT for at least 
8 [6 – 11] years.  The median total cumulative dose 
of the patients receiving agalsidase-b was 0.93 ml/kg 
[0.83 – 1.10] and agalsidase-a 0.20 ml/kg [0.18 – 0.21]. 
Females were started on ERT at 36 [21 – 54] years, 
males at 39 [28 – 49] years of age. Among treated 
females, the primary cause of ERT initiation was 
acroparesthesia (n=8), cardiomypathy (n=7), stroke 
(n=3), renal involvement diagnosed by biopsy (n=1), 
cardiomypathy and renal involvement (n=2). 
Overall, 39 patients received agalsidase-a and four agalsidase-b throughout the observational 
period. Six patients were switched from agalsidase-b 
Fig. 1. Study flow-chart of the main analysis.
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Relationship 
between age 
and kidney 
f u n c t i o n : 
baseline data
The relation-
ship of age and 
eGFR at initia-
tion of ERT was 
investigated with 
Eq. (1), i.e. age at 
baseline vs. eGFR 
at baseline. Base-line data from fe-
male FD patients 
(n=54) showed a linear relation-
ship with a sig-
nificant (p<0.01) 
negative slope and a reasonable 
coefficient of de-
termination (R^2 
= 0.57). Notably, 
only 7% of female 
FD patients (n = 
4) were staged in 
CKD 3 (< 60 ml/
Fig. 2.  Relationship of age and eGFR at baseline. The relationship of age and eGFR at baseline is visualized 
for female (n=54) in the left panel A and male (n=26) in the right panel B. Every diamond corresponds to 
one patient. Linear regression Eq. (1) is shown as solid blue line and the dashed black line marks beginning 
of the CKD stage three and higher. Coefficient of determination R^2 and slope b are indicated in the panels.
Table 2. Baseline characteristics of treated and untreated patients with the Clas-
sic phenotype of Fabry disease patients included in disease progression model
min/m1.73m^2) at first visit. The age of these four females was 60 years or higher. Baseline 
data from male FD patients (n=25) also had a significant (p<0.01) negative slope, although 
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with a lower coefficient of deter-
mination (R^2<0.29). In contrast 
to female FD patients, 24% of the 
male FD patients (n=6) were staged 
in CKD 3 or 4 at first visit. The ages 
of these six males ranged from 22 
to 52 years. One of these six pa-
tients showed an eGFR value below 
30 ml/min/1.73m^2 (CKD stage 4). 
Hence, approximately one-fourth 
of the male FD patients in the in-
vestigated cohort had an already 
significant renal impairment pri-
or to initiation of ERT. In Figure 2, 
the results for female (panel A) and 
male (panel B) subjects are shown. 
Estimates of model parameters and 
their variability are summarized in 
Table 1.
Change in kidney function and 
covariate effects: longitudinal 
data
FD patients with more than 
one creatinine measurement were 
considered (n = 67). Baseline characteristics of treated and 
untreated FD patients are presented 
in Table 2, the genotype information 
in Table 3. Among females, 22 
were ‘untreated’ (total number of 
measurements = 82). To account 
for the relationship between age 
and eGFR at initiation of ERT, i.e., 
age at baseline was a significant 
covariate on eGFRBase(p<0.05), this 
covariate effect was included in all 
consecutive disease progression 
models. After accounting for this 
age effect on eGFR at baseline, 
values of mean arterial pressure 
(MAP), body weight (WT) and body 
mass index (BMI) at baseline had 
no influence on eGFRBase and age 
at baseline showed no effect on the eGFRSlope.  Furthermore, time 
varying covariates WT, BMI and 
MAP did not influence the eGFRSlope. 
Estimates of covariate effects are 
provided in Table 4.
A total of 45 ‘treated’ FD 
patients (females, n = 21, males, 
n = 24) with a total of 317 
Table 3. Information about the genotype of the 67 Classic pa-
tients who were included into the longitudinal model of the 
kidney disease progression
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measurements were available. Sex 
had a significant effect on eGFRSlope. 
After accounting for this sex effect, 
age, WT, BMI and MAP at baseline 
showed no effects on eGFRBase or 
eGFRSlope. 
No clear effects of angiotensin-
converting enzyme (ACE)-inhibitors and angiotensin blockers 
(ARB) on eGFR slopes were found. 
Estimates of covariate effects are 
listed in Table 4. Female FD patients without ERT had a slight decrease in eGFR (eGFRSlope= 
-0.006 ml/min/1.73m^2/month) (Figure 3A), whereas ‘treated’ females showed a marginal 
increase of eGFR over time (eGFRSlope= 0.0428 ml/min/1.73m^2/month) (Figure 3B). 
Difference of the eGFR slopes between ‘untreated’ females and those with ERT was not 
statistically significant. Further magnitude of ERT effect on eGFR slope was marginal in 
females with stable, almost unchanged kidney function over time. In contrast, males with 
ERT had a noticeable decrease of eGFR over time (eGFRSlope= -0.256 ml/min/1.73m^2/
month), which was significantly different from that observed in females on ERT (p<0.01) 
(Figure 3C). 
There was no difference in effects of agalsidase-α and -β on eGFR slopes. However, 
the number of patients on agalsidase-β was small. The actual administered ERT dose had 
no clear effect on eGFR slope. In patients with eGFR at baseline below and above 60 ml/
min/1.73m^2, the eGFR slopes were similar. In addition, a covariate test of eGFR at baseline 
directly at the slope showed no significant effect. 
Analysis of albuminuria and proteinuria 
Protein/creatinine ratios in the urine were available from 46 patients with a total of 
174 measurements and albumin/creatinine ratios from 51 patients with a total of 217 
measurements. No covariate effects on the slope of these ratios over time were found, 
especially no ERT dependent difference. At baseline, the urine albumin/creatinine and 
protein/creatinine ratios were significantly higher in males than in females. However, since 
longitudinal albuminuria and proteinuria data were associated with a high variability, no disease 
Table 4. Model parameters and covariate effects of the longitudinal change in eGFR data analysis
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progression model was 
developed. 
Relationship of eGFR 
slope and albuminuria 
at baseline
Kidney function 
decrease over time, 
characterized by eGFR 
slopes, was significantly 
(p < 0.05) less severe in 
the first (albuminuria at 
baseline < 3 mg/mmol; 
median slope = 0.019) and 
second (3 - 30 mg/mmol, 
median slope = 0.014) 
group as compared to the 
the third (> 30 mg/mmol; 
median slope = -0.371) 
category (Figure 4). Fig. 4. Comparison of eGFR slopes according to albuminuria categories.
Fig. 3. The eGFR change over time. Panel A un-
treated females (n=22), panel B treated females 
(n=21) and panel C treated males (n=24). The dots 
represent the eGFR data. The solid blue lines are 
the mean eGFR change over time of the typical pa-
tient obtained by non-linear mixed effect modeling 
with Eq. (2). Shaded areas visualize the 5 and 95 
% confidence intervals calculated based on 1000 
simulated populations. 
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Relation of eGFR slope and serum-mediated ERT inhibition
Three of 15 treated males showed a significant inhibition of >50%: first male currently 
52 years old, ERT start with 38 years of age, second male currently 57 years old, ERT start 
with 44 years of age, third male currently 51 years old, ERT start with 39 years of age. Their 
eGFR slopes were not significantly different to the non-inhibiting male population (data not 
shown). 
No female showed a significant serum-mediated ERT inhibition in this cohort.
Clinical events
Overall, 27 events occurred in 18 of 67 Classical patients who were included into the 
dynamic analysis. Among treated females, 1 suffered a new-onset AF, 5 strokes, 1 needed 
a pacemaker and 2 died (reason unknown). No events occurred among untreated females. 
Among treated males, 3 patients received a kidney transplantation, 4 suffered a new-onset 
aerial fibrillation (AF), 4 strokes, 1 myocardial infarction, 2 needed a pacemaker and 3 died 
(1 due to sepsis, 2 unknown) (Table 2).
Later-Onset phenotype patients
Five males with the mutations c.902G>A (p.Arg301Gln) (two unrelated males); 
c.1196G>C (p.Trp399Ser); c.352C>T (p.Arg118Cys); c.644A>G (p.Asn215Ser) had a Later-
Onset phenotype. 
One of the males with the mutation c.902G>A was 51 years old when he was diagnosed 
and started on ERT with an advanced kidney failure (eGFR of 15 ml/min/1.73m^2). The 
other male with the same mutation was 36 years old when he was diagnosed and started 
on ERT with a normal eGFR and proteinuria of 0.6 g/24 hours. The male with the mutation 
c.1196G>C was 42 years old when he was diagnosed with proteinuria of 1.8 g/24 hours 
and eGFR of 62 ml/min/1.73m^2. He unfortunately rejected ERT. The other two males with 
c.352C>T and c.644A>G were 74 and 36 years old respectively, and had a normal kidney 
function without proteinuria, both received ERT. 
Four females with the mutations, c.902G>A (p.Arg301Gln) (two related females), 
c.416A>G (p.Asn139Ser), c.337T>C (p.Phe113Leu) had a Later-Onset phenotype. 
One of the both females with the mutation c.902G>A (mother) was 61 years old when 
diagnosed and started on ERT with an eGFR of 88 ml/min/1.73m^2 and proteinuria of 0.8 
g/24 hours. Her 25-year-old daughter, had a normal kidney function without proteinuria and 
needed no ERT. Also the 40-year-old female with the mutation c.416A>G and the 33-year-old 
with c.337T>C had normal kidney function and needed no ERT. 
This group did not form a basis for comparison due to its small sample size and 
heterogeneity and was therefore excluded from the analysis.   
Discussion
This analysis of a large well documented genetically proven homogeneous group of 
Classic FD phenotype patients with and without ERT investigated longitudinal eGFR data 
over a long follow-up period. To account for both, individual and population level disease 
progression, non-linear mixed effect modelling (NLME) was applied. Although NLME is 
frequently applied in clinical drug development, to our knowledge, it is the first time that 
this method was utilized to characterize progression of the Fabry nephropathy over time, 
quantify effects of ERT, as well as key covariates on kidney function. Previous studies used 
linear multivariate regression models for outcome analyses as a common statistical tool [16, 
31, 32]. 
The developed model included the relationship of age at baseline on eGFR at baseline. 
The finding that kidney function decreases with age is a known fact for the normal population 
[33] as well as patients with FD [1, 2]. Agalsidase-a and agalsidase-β had a dose-independent 
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effects on the development of kidney function in this cohort. Additionally, covariates such as 
mean arterial pressure, BMI, treatment with ACE-inhibitors and ARB had no influence on 
the eGFR slope and proteinuria. By modeling, kidney function remained stable in female 
FD patients without ERT (eGFR slope -0.07 ml/min/1.73m^2 per year) and those with ERT 
(0.52 ml/min/1.73m^2 per year) without a significant difference between these two slopes. 
In contrast, male FD patients showed a clear decline of kidney function over time despite 
ERT (eGFR slope -3.07 ml/min/1.73m^2 per year), which appears to be faster than that 
observed in normal population [33]. According to the developed model, male FD patients 
can pass through several CKD stages ending up with end-stage renal disease within 15 years 
after initiation of ERT later in the disease. 
Importantly, the majority of symptomatic female patients received ERT because of 
neurological and cardiovascular symptoms and events. In 3 of 21 treated female patients, 
ERT was initiated due to FD-related nephropathy. The baseline protein excretion and need 
of ACE-inhibitors therapy seems to be higher in the treated than in the untreated female 
group (Table 2). Therefore, the treated female patients might have had a more pronounced 
kidney involvement at baseline than those without ERT (Table 2). Thus, enzyme replacement 
therapy could have stabilized the kidney function in these females. 
In contrast, ERT showed no clear treatment-related benefit on the development of 
Fabry nephropathy in male patients in this cohort. One of the possible reasons for the latter 
observation could be that the initiation of ERT was relatively late, i.e. after 35 years of age. 
This is an “old” FD population where a great proportion of the patients had advanced kidney 
disease, when ERT was initiated and offered to all FD patients in 2001. Additionally, as FD 
is rare, patients experience a delayed diagnosis also resulting in treatment delay [34]. In 
agreement with our results, a significant loss of renal function over time has repeatedly been 
demonstrated in patients with FD even under ERT. In an analysis of Fabry Outcome Survey, 
Beck and co-authors demonstrated for example that the renal disease progression under 
ERT is more accelerated in patients with already impaired kidney function at baseline [31]. 
These findings support the assumption that early therapy initiation benefit kidney function. 
Of note, the eGFR slopes of the three males with an endogenous serum-mediated 
inhibition of the recombinant enzyme were not significantly different to the non-inhibiting 
male population. A possible explanation of this finding is that in this cohort with late ERT 
initiation, the ERT effects were limited due to the advanced disease stage at baseline in 
both - inhibiting and non-inhibiting - groups. This finding is in agreement with the main 
study results. However, these studies are limited since the sample size of inhibiting males 
is small. Importantly, no female showed a significant serum-mediated ERT inhibition in this 
cohort, also as shown by Linthorst et al, Rombach et al and Lenders et al [26-28]. This is the 
first study to show that obviously, classical females do not develop a serum-mediated ERT 
inhibition even after many years of ERT.
Early FD diagnosis could prevent kidney disease progression through the timely 
initiation of treatment. As shown in our results, the disease progression was accelerated 
if ERT patients already had a more severe albuminuria at baseline.  Studies suggest that 
maximal treatment effect in Fabry nephropathy can be achieved at an early stage with 
normal or almost normal kidney function [11, 35, 36]. Tondel et al have described beneficial 
effects of ERT detected in kidney biopsies regarding clearance of glomerular endothelial 
and mesangial cell inclusions in patients with well-preserved renal function [11, 35]. A 
recent study by Germain and colleagues showed that less affected individuals with a better 
preserved kidney function at baseline benefited from ERT, experiencing better renal and 
cardiovascular outcomes during the observational period [36]. Moreover, in male FD 
patients, enhanced therapeutic outcomes may occur if we increase the ERT dose [35, 37, 38], 
or frequency of infusions [39],  in combination with intensified additional medication such 
as ARBs and ACE inhibitors [16].  In patients with amenable mutations, pharmacological 
chaperones have been shown as a useful therapeutic alternative [40, 41]. Their combination 
with ERT could further increase therapeutic effects [42], this assumption needs to be 
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confirmed in clinical studies. Furthermore, enhanced uptake of α-gal A into target cells [43] 
and substrate reduction  therapy [44] have been tested in mouse model experiments and can 
possibly be implemented in human studies in the future, especially in combination with ERT. 
It can’t be excluded that our male FD patients had experienced treatment benefit despite 
their deterioration of kidney function. Studies demonstrated a long-term renal stabilization 
following ERT in FD patients [12, 14, 45, 46]. However, placebo-controlled clinical trials 
in Fabry nephropathy are scarce and the choice of an appropriate control group in the 
assessment of the treatment response especially in males remains crucial.
Several limitations merit consideration. First, we included only renal parameters of 
adolescent and adult FD patients into the longitudinal mathematical model. The time course 
of eGFR could be non-linear in children with FD. Therefore, further investigations with 
longitudinal models including pediatric and adult FD patients are warranted. Such expanded 
model might allow evaluating effects of timely ERT initiation in pediatric males with classical 
phenotype. Second, we did not test a larger variation of ERT dose on Fabry nephropathy 
development as the really applied ERT dose did not greatly vary in this cohort. We therefore 
cannot exclude a possible dose-dependent beneficial effect on Fabry nephropathy.  Third, we 
did not systematically conduct renal biopsies in our patients, also LysoGb3 measurements 
over time were not available in this “old” FD population. However, follow-up kidney biopsies 
and LysoGb3 in FD patients could assess treatment response, exclude renal pathologies 
beyond Fabry nephropathy and confirm diagnosis in uncertain cases [47-49]. Fourth, 
mathematical disease progression modeling should ideally contain histological findings 
based on scoring system for renal pathology in Fabry nephropathy [50]. Moreover, early 
renal tissue biomarkers need to be added to the pharmacometric modeling approaches to 
develop prognostic markers for pediatric FD patients.
The strength of the study is that we analyzed a large well documented genetically proven 
homogeneous group including only patients with the Classic phenotype of FD. 
Conclusion
No clear therapeutic effect of enzyme replacement therapy on kidney function in adult 
patients with Fabry disease was found, presumably because ERT was initiated late in the 
disease. Interpretation of these findings should take into account that the study is not 
randomized and lacks a placebo controlled group.
In a future project, mathematical disease progression modeling will be applied to 
characterize ERT effects on kidney function in pediatric FD patients. Further investigations 
are warranted to clarify whether earlier ERT initiation, higher ERT dose or more intensive 
therapies can preserve kidney function, especially in pediatric and adult male FD patients. 
Mathematical disease progression modeling can add substantial knowledge in the assessment 
of the therapeutic effects of ERT in female and male FD patients.
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